Stocks · News reference
Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwideOrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pharming Says FDA Grants Priority Review For Joenja In Children With APDS Weighing 13 To 27 Kg; Decision Due January 30, 2027
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
Pharming Wins FDA Approval For Joenja In Children Ages 4 To 11 Who Weigh At Least 27kg, With New 40mg/50mg Twice-Daily Doses Expected In October
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be